HCA
LOGC

Harbor Capital Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Harbor Capital Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-235,292
Closed -$85K – 161
2022
Q2 		$85K Buy
235,292
+8,561
+4% +$4.33K 0.06% 160
2022
Q1 		$154K Sell
226,731
-55,847
-20% -$61.3K 0.07% 139
2021
Q4 		$653K Buy
+282,578
New +$956K 0.24% 86

Other funds holding LOGC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Harbor Capital Advisors's LOGC Position: Q3 2022 in Review

Harbor Capital Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 235,292 shares — an estimated $85K sold.

Harbor Capital Advisors first reported a position in LOGC in Q4 2021 and held it in 3 quarters. The position peaked at $653K in Q4 2021. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

  • Harbor Capital Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Harbor Capital Advisors sold 235,292 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $85K.
  • Harbor Capital Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Harbor Capital Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $653K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Harbor Capital Advisors's 13F filing for Q3 2022, filed 28 Oct 2022.